vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Ponce Financial Group, Inc. (PDLB). Click either name above to swap in a different company.
Ponce Financial Group, Inc. is the larger business by last-quarter revenue ($31.4M vs $18.7M, roughly 1.7× CytomX Therapeutics, Inc.). Ponce Financial Group, Inc. runs the higher net margin — 36.3% vs -0.8%, a 37.1% gap on every dollar of revenue. On growth, Ponce Financial Group, Inc. posted the faster year-over-year revenue change (37.6% vs -25.7%). Ponce Financial Group, Inc. produced more free cash flow last quarter ($54.6M vs $-15.8M). Over the past eight quarters, Ponce Financial Group, Inc.'s revenue compounded faster (23.7% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Ponce Financial Group, Inc. is a U.S.-based financial holding company operating Ponce Bank as its core subsidiary. It serves multicultural, immigrant and low-to-moderate income communities in the New York metro area, offering retail and commercial banking products including deposits, mortgages, small business financing and personal credit.
CTMX vs PDLB — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $31.4M |
| Net Profit | $-154.0K | $10.1M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | 43.6% |
| Net Margin | -0.8% | 36.3% |
| Revenue YoY | -25.7% | 37.6% |
| Net Profit YoY | 97.6% | 245.6% |
| EPS (diluted) | — | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $31.4M | ||
| Q3 25 | — | $26.7M | ||
| Q2 25 | $18.7M | $26.5M | ||
| Q1 25 | $50.9M | $24.6M | ||
| Q4 24 | $38.1M | $22.8M | ||
| Q3 24 | $33.4M | $20.2M | ||
| Q2 24 | $25.1M | $20.2M | ||
| Q1 24 | $41.5M | $20.5M |
| Q4 25 | — | $10.1M | ||
| Q3 25 | — | $6.5M | ||
| Q2 25 | $-154.0K | $6.1M | ||
| Q1 25 | $23.5M | $6.0M | ||
| Q4 24 | $18.9M | $2.9M | ||
| Q3 24 | $5.7M | $2.4M | ||
| Q2 24 | $-6.5M | $3.2M | ||
| Q1 24 | $13.8M | $2.4M |
| Q4 25 | — | 43.6% | ||
| Q3 25 | — | 32.8% | ||
| Q2 25 | -6.9% | 30.2% | ||
| Q1 25 | 44.4% | 32.5% | ||
| Q4 24 | 46.4% | 19.6% | ||
| Q3 24 | 12.3% | 15.2% | ||
| Q2 24 | -33.7% | 21.8% | ||
| Q1 24 | 28.1% | 18.3% |
| Q4 25 | — | 36.3% | ||
| Q3 25 | — | 24.3% | ||
| Q2 25 | -0.8% | 23.0% | ||
| Q1 25 | 46.2% | 24.2% | ||
| Q4 24 | 49.6% | 14.1% | ||
| Q3 24 | 17.2% | 12.1% | ||
| Q2 24 | -26.0% | 15.8% | ||
| Q1 24 | 33.3% | 11.8% |
| Q4 25 | — | $0.43 | ||
| Q3 25 | — | $0.27 | ||
| Q2 25 | — | $0.25 | ||
| Q1 25 | — | $0.25 | ||
| Q4 24 | — | $0.11 | ||
| Q3 24 | — | $0.10 | ||
| Q2 24 | — | $0.14 | ||
| Q1 24 | — | $0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $126.2M |
| Total DebtLower is stronger | — | $596.1M |
| Stockholders' EquityBook value | $119.9M | $541.5M |
| Total Assets | $175.1M | $3.2B |
| Debt / EquityLower = less leverage | — | 1.10× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $126.2M | ||
| Q3 25 | — | $146.6M | ||
| Q2 25 | $49.0M | $126.6M | ||
| Q1 25 | $47.6M | $129.9M | ||
| Q4 24 | $38.1M | $139.8M | ||
| Q3 24 | $40.6M | $155.8M | ||
| Q2 24 | $43.2M | $103.2M | ||
| Q1 24 | $36.2M | $134.7M |
| Q4 25 | — | $596.1M | ||
| Q3 25 | — | $521.1M | ||
| Q2 25 | — | $536.1M | ||
| Q1 25 | — | $521.1M | ||
| Q4 24 | — | $596.1M | ||
| Q3 24 | — | $580.4M | ||
| Q2 24 | — | $680.4M | ||
| Q1 24 | — | $680.4M |
| Q4 25 | — | $541.5M | ||
| Q3 25 | — | $529.8M | ||
| Q2 25 | $119.9M | $521.1M | ||
| Q1 25 | $25.0M | $513.9M | ||
| Q4 24 | $-456.0K | $505.5M | ||
| Q3 24 | $-23.5M | $504.6M | ||
| Q2 24 | $-31.2M | $497.7M | ||
| Q1 24 | $-31.7M | $493.7M |
| Q4 25 | — | $3.2B | ||
| Q3 25 | — | $3.2B | ||
| Q2 25 | $175.1M | $3.2B | ||
| Q1 25 | $98.5M | $3.1B | ||
| Q4 24 | $120.5M | $3.0B | ||
| Q3 24 | $139.0M | $3.0B | ||
| Q2 24 | $159.2M | $2.8B | ||
| Q1 24 | $184.7M | $2.8B |
| Q4 25 | — | 1.10× | ||
| Q3 25 | — | 0.98× | ||
| Q2 25 | — | 1.03× | ||
| Q1 25 | — | 1.01× | ||
| Q4 24 | — | 1.18× | ||
| Q3 24 | — | 1.15× | ||
| Q2 24 | — | 1.37× | ||
| Q1 24 | — | 1.38× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $55.6M |
| Free Cash FlowOCF − Capex | $-15.8M | $54.6M |
| FCF MarginFCF / Revenue | -84.6% | 173.9% |
| Capex IntensityCapex / Revenue | 0.1% | 3.1% |
| Cash ConversionOCF / Net Profit | — | 5.48× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $74.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $55.6M | ||
| Q3 25 | — | $1.4M | ||
| Q2 25 | $-15.8M | $6.2M | ||
| Q1 25 | $-21.0M | $13.1M | ||
| Q4 24 | $-19.9M | $7.2M | ||
| Q3 24 | $-20.7M | $-14.6M | ||
| Q2 24 | $-19.5M | $-2.6M | ||
| Q1 24 | $-26.0M | $1.5M |
| Q4 25 | — | $54.6M | ||
| Q3 25 | — | $786.0K | ||
| Q2 25 | $-15.8M | $5.9M | ||
| Q1 25 | $-21.2M | $12.9M | ||
| Q4 24 | $-20.0M | $4.5M | ||
| Q3 24 | $-20.7M | $-15.0M | ||
| Q2 24 | $-19.6M | $-2.6M | ||
| Q1 24 | $-26.2M | $-315.0K |
| Q4 25 | — | 173.9% | ||
| Q3 25 | — | 2.9% | ||
| Q2 25 | -84.6% | 22.4% | ||
| Q1 25 | -41.6% | 52.6% | ||
| Q4 24 | -52.5% | 19.7% | ||
| Q3 24 | -62.1% | -74.1% | ||
| Q2 24 | -78.2% | -13.0% | ||
| Q1 24 | -63.1% | -1.5% |
| Q4 25 | — | 3.1% | ||
| Q3 25 | — | 2.3% | ||
| Q2 25 | 0.1% | 1.0% | ||
| Q1 25 | 0.2% | 0.6% | ||
| Q4 24 | 0.2% | 11.9% | ||
| Q3 24 | 0.1% | 2.0% | ||
| Q2 24 | 0.4% | 0.3% | ||
| Q1 24 | 0.3% | 8.7% |
| Q4 25 | — | 5.48× | ||
| Q3 25 | — | 0.21× | ||
| Q2 25 | — | 1.01× | ||
| Q1 25 | -0.89× | 2.20× | ||
| Q4 24 | -1.05× | 2.46× | ||
| Q3 24 | -3.61× | -5.99× | ||
| Q2 24 | — | -0.80× | ||
| Q1 24 | -1.89× | 0.61× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
PDLB
Segment breakdown not available.
